Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission.
Fiche publication
Date publication
janvier 2018
Journal
Oncotarget
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DECONINCK Eric
Tous les auteurs :
Saraceni F, Labopin M, Hamladji RM, Mufti G, Socié G, Shimoni A, Delage J, Deconinck E, Chevallier P, Blaise D, Sanz J, Huynh A, Forcade E, Savani BN, Mohty M, Nagler A,
Lien Pubmed
Résumé
A preparatory regimen consisting of thiotepa-busulfan-fludarabine (TBF) has been associated with reduced relapse in patients with haematological malignancies after haploidentical and cord blood transplants; however, few data exist regarding TBF conditioning in sibling (MSD) and unrelated donor (URD) transplants for AML.
Mots clés
acute myeloid leukemia (AML), allogeneic transplantation, busulfan-fludarabine (BF), myeloablative conditioning (MAC), thiotepa-busulfan-fludarabine (TBF)
Référence
Oncotarget. 2018 Jan 9;9(3):3379-3393